6 Meridian purchased a new position in shares of LeMaitre Vascular Inc (NASDAQ:LMAT) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 20,489 shares of the medical instruments supplier’s stock, valued at approximately $635,000. 6 Meridian owned 0.10% of LeMaitre Vascular at the end of the most recent quarter.
Several other hedge funds have also recently added to or reduced their stakes in the stock. Bank of Montreal Can lifted its position in shares of LeMaitre Vascular by 99.1% in the 4th quarter. Bank of Montreal Can now owns 1,113 shares of the medical instruments supplier’s stock worth $26,000 after purchasing an additional 554 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of LeMaitre Vascular by 151.7% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,513 shares of the medical instruments supplier’s stock worth $36,000 after acquiring an additional 912 shares in the last quarter. Quantamental Technologies LLC bought a new position in shares of LeMaitre Vascular during the 4th quarter worth approximately $49,000. Municipal Employees Retirement System of Michigan acquired a new position in LeMaitre Vascular during the 4th quarter valued at approximately $106,000. Finally, Metropolitan Life Insurance Co. NY increased its stake in LeMaitre Vascular by 373.8% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 5,629 shares of the medical instruments supplier’s stock valued at $133,000 after purchasing an additional 4,441 shares in the last quarter. 76.16% of the stock is owned by hedge funds and other institutional investors.
A number of research analysts have issued reports on LMAT shares. Zacks Investment Research lowered shares of LeMaitre Vascular from a “hold” rating to a “sell” rating in a research note on Thursday, February 7th. Lake Street Capital restated a “hold” rating and set a $24.00 price target on shares of LeMaitre Vascular in a research note on Wednesday, January 23rd. ValuEngine lowered shares of LeMaitre Vascular from a “hold” rating to a “sell” rating in a research note on Monday, January 7th. Roth Capital reiterated a “neutral” rating on shares of LeMaitre Vascular in a research note on Thursday, February 21st. Finally, BidaskClub upgraded shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a research note on Friday, March 1st. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $31.00.
LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings results on Wednesday, May 1st. The medical instruments supplier reported $0.17 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.19 by ($0.02). The firm had revenue of $28.48 million for the quarter, compared to analysts’ expectations of $27.94 million. LeMaitre Vascular had a return on equity of 17.71% and a net margin of 21.73%. The business’s quarterly revenue was up 9.6% on a year-over-year basis. During the same period last year, the company posted $0.19 earnings per share. As a group, equities analysts predict that LeMaitre Vascular Inc will post 0.84 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 6th. Shareholders of record on Wednesday, May 22nd will be issued a dividend of $0.085 per share. This represents a $0.34 annualized dividend and a yield of 1.23%. The ex-dividend date of this dividend is Tuesday, May 21st. LeMaitre Vascular’s payout ratio is 40.48%.
In other LeMaitre Vascular news, insider Trent G. Kamke sold 16,604 shares of the stock in a transaction on Friday, February 22nd. The shares were sold at an average price of $29.63, for a total transaction of $491,976.52. Following the transaction, the insider now directly owns 19,857 shares of the company’s stock, valued at $588,362.91. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 19.60% of the company’s stock.
LeMaitre Vascular Profile
LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.
Featured Article: Marijuana Stocks Investing Considerations
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.